Genentech Pulmozyme
Executive Summary
Safety data in patients three months to five years old added to labeling Feb. 24. In the pediatric study for dornase alfa inhalation solution for cystic fibrosis, 98 patients - 65 aged three months to under five years and 33 aged from five through 10 years - received 2.5 mg Pulmozyme for two weeks. Patients from the younger group showed a higher rate of cough (45% vs. 30%) and moderate to severe cough (37% vs. 18%), as well as rhinitis (35% vs. 27%) and rash (6% vs. 0%)...